Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Pacira Biosciences Inc (PCRX) USD0.001

Sell:$45.63 Buy:$45.69 Change: $0.17 (0.37%)
NASDAQ:0.20%
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Sell:$45.63
Buy:$45.69
Change: $0.17 (0.37%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Sell:$45.63
Buy:$45.69
Change: $0.17 (0.37%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).

Contact details

Address:
5 Sylvan Way Ste 300
PARSIPPANY
07054-3813
United States
Telephone:
+1 (973) 2543560
Website:
www.pacira.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PCRX
ISIN:
US6951271005
Market cap:
$1.90 billion
Shares in issue:
41.73 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • David Stack
    Chairman of the Board, Chief Executive Officer
  • Max Reinhardt
    President
  • Charles Reinhart
    Chief Financial Officer
  • Kristen Williams
    Chief Administrative Officer, General Counsel, Secretary
  • Charles Laranjeira
    Chief Technical Officer
  • Dennis McLoughlin
    Chief Commercial Officer
  • Richard Scranton
    Chief Medical Officer
  • Roy Winston
    Chief Clinical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.